A cyberattack on fintech firm SitusAMC has major US banks scrambling to assess potential data exposure tied to mortgages and ...
A pill version of Novo Nordisk A/S’s Ozempic failed to slow the progression of Alzheimer’s disease in a pair of high-risk studies that aimed to open up a new use for blockbuster obesity drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback